BioSpace News Archive

Global biopharmaceutical company enables real-time inspection readiness and improves CRO collaboration

Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development

Leading NGS QC Software is integrated into their Philips IntelliSpace Genomics Platform

Livongo Health, the leading consumer digital health company empowering people with chronic conditions to live better and healthier lives, announced today it has acquired Chicago-based Retrofit, a leading provider of weight-management and disease-prevention programs.

Stoke Therapeutics, Inc., a biotechnology company developing therapeutics that increase gene expression to treat a wide array of diseases caused by genetic insufficiency, today announced the expansion of its leadership team to enhance its deep expertise in oligonucleotide chemistry and rare disease research and development.

Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE® (glatiramer acetate injection) and AUSTEDO® (deutetrabenazine) tablets data highlight Teva’s ongoing clinical research

Data show ability of destabilizing domain technology platform to regulate expression of secreted and membrane-bound proteins in cell therapies

PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells.

ViaCyte, Inc., a privately held regenerative medicine company, today announced that it has been awarded a Small Business Innovative Research (SBIR) Phase II Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support the further development of functional human beta cells in vitro.

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting (Liverpool, U.K., 26-29 April 2018).